STOCK TITAN
  1. Home
  2. News
  3. CRBP

Corbus Pharmaceuticals Holdings Inc - CRBP STOCK NEWS

Welcome to our dedicated news page for Corbus Pharmaceuticals Holdings (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corbus Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corbus Pharmaceuticals Holdings's position in the market.

News
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the release of the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) and the upcoming presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. The study, conducted by Corbus's partner CSPC Pharmaceutical Group in China, aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of SYS6002 in patients with advanced solid tumors who have failed standard treatment. The presentation will include data as of December 2023 and will focus on the potential of SYS6002 to reduce toxicities associated with enfortumab vedotin and increase clinical convenience and patient compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
clinical trial
-
News
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) announces FDA clearance for investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates robust anti-tumor activity in solid tumor models. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
clinical trial
-
News
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that the Phase 1 clinical data from a dose escalation study with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. CRB-701 is a next-generation antibody-drug-conjugate targeting nectin-4, showing promising pre-clinical data differentiation from enfortumab vedotin. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer, with approved use in late metastatic urothelial cancer and an expanded label for use in combination with KEYTRUDA for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
News
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. provided a corporate update, including the progress of their CRB-701, CRB-601, and CRB-913 programs. The company also reported a net loss of $10.1 million for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
earnings
-
News
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Rhea-AI Summary
Corbus Pharmaceuticals announces positive results from pre-clinical studies on CRB-601 anti-aVb8 integrin monoclonal antibody. The studies demonstrate robust anti-tumor activity and support the hypothesis that effective blockade of latent TGFβ activation enhances immune cell invasion in the tumor microenvironment. CRB-601 shows increased activity in tumors expressing αvβ8, providing a promising biomarker for patient selection. The company plans to submit its Investigational New Drug application for CRB-601 by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
clinical trial
-
News
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
Rhea-AI Summary
Corbus Pharmaceuticals announces positive results of pre-clinical study on CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
Rhea-AI Summary
Corbus Pharmaceuticals to host 'Meet the Expert' event on development of Nectin-4 antibody drug conjugate CRB-701, featuring renowned oncology experts. Panel will discuss unmet needs, Nectin-4 biology, and differentiation features of CRB-701. Registration link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences
-
News
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Rhea-AI Summary
Corbus Pharmaceuticals announces acceptance of CRB-601 abstract for presentation at SITC Annual Meeting. CRB-601 is a potential breakthrough in oncology treatment. IND submission expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences clinical trial
-
News
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Summary
Corbus Pharmaceuticals to present pre-clinical data on CRB-701 ADC at 2023 AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
conferences clinical trial
News
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. provided a corporate update and reported financial results for Q2 2023. The Phase 1 trial of CRB-701 in China is ahead of schedule, with dose escalation completion expected in Q4 2023. The U.S. clinical trial for CRB-701 is planned to start in Q1 2024. Preliminary clinical data shows CRB-701 has a longer half-life and reduced levels of circulating free MMAE compared to PADCEV®. The IND submission for CRB-601 is on track for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
earnings
Stock CRBP logo
Corbus Pharmaceuticals Holdings Inc

Nasdaq:CRBP

CRBP Rankings

#3266 Ranked by Market Cap
#601 Ranked by Stock Gains
N/A Ranked by Dividends

CRBP Stock Data

429.22M
6.77M
0.69%
56.95%
4.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Norwood

About CRBP

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.